Minimally Invasive and Novel Therapeutics (MINT) in Foregut Disease
Associated Schools
![Harvard Medical School](/sites/default/files/styles/4_5_xsmall/public/schools/logo/harvard-medical.png?itok=IbibkvQ3)
Apply new knowledge in the management of patients with reflux and swallowing disorders
Develop treatment strategies based on current evidence and expert-opinion
Compare and contrast standard-of-care management with cutting-edge treatments
The annual hybrid Minimally Invasive and Novel Therapeutics (MINT) continuing medical education (CME) course, seeks to equip clinicians with advanced technical knowledge of the latest surgical and endoscopic procedures needed to diagnose and treat foregut disease utilizing novel educational formats such as video-based learning to encourage “technique transfer”.
We further hope to foster ongoing collaboration between gastroenterologists, surgeons, advanced practice providers, nurses, and dietitians to optimize the multidisciplinary care of patients with foregut digestive disease.
This is an accredited, livestreamed and in-person course offered by Massachusetts General Hospital. This course is targeted to Specialty Physicians, Nurses , Nurse Practitioners , Physician Assistants , Residents, Nutritionists, and Dietitians.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.